🇺🇸 Alpha1-Proteinase Inhibitor in United States

10 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 10

Most-reported reactions

1. Acinetobacter Infection — 1 report (10%)
2. Asthma — 1 report (10%)
3. Bronchiolitis — 1 report (10%)
4. Concomitant Disease Progression — 1 report (10%)
5. Deep Vein Thrombosis — 1 report (10%)
6. Drug Ineffective — 1 report (10%)
7. Dyspnoea Exertional — 1 report (10%)
8. Fatigue — 1 report (10%)
9. Multiple Organ Dysfunction Syndrome — 1 report (10%)
10. Musculoskeletal Chest Pain — 1 report (10%)

Source database →

Frequently asked questions

Is Alpha1-Proteinase Inhibitor approved in United States?

Alpha1-Proteinase Inhibitor does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Alpha1-Proteinase Inhibitor in United States?

Baxalta now part of Shire is the originator. The local marketing authorisation holder may differ — check the official source linked above.